Nilotinib therapy after resistance to imatinib

Nilotinib therapy after resistance to imatinib

Authors

  • Raffaele Porrini Ematologia “Sapienza” Università di Roma, Facoltà di Medicina e Psicologia
  • Enrico Montefusco Ematologia “Sapienza” Università di Roma, Facoltà di Medicina e Psicologia


DOI:

https://doi.org/10.7175/cmi.v6i2S.1137

Keywords:

Chronic myeloid leukaemia, Nilotinib, Resistance to imatinib

Abstract

In this article we present the case of a 43-year-old man with chronic myeloid leukemia (CML) successfully treated with nilotinib. At presentation we started him on imatinib at standard dose of 400 mg/day but after 36 months of treatment the patient didn’t achieve a molecular response. We switched him on second-generation tyrosine kinase inhibitor (TKI), nilotinib, at the dose of 800 mg/day. After twelve months on nilotinib the patient obtained a complete molecular response. During treatment with nilotinib we did not observe any drug-related toxicity.

Downloads

Published

2015-10-13

Issue

Vol. 6 No. 2S (2012)

Section

Case report

License

Authors who publish with this journal agree to the following terms:
    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial 4.0 Licence that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
    4. Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)